Liquidia gets FDA Fast Track for YUTREPIA in Raynaud's
Liquidia said the FDA granted Fast Track designation to YUTREPIA (treprostinil) inhalation powder for Raynaud’s phenomenon associated with systemic sclerosis.
Liquidia announced FDA Fast Track designation for YUTREPIA (treprostinil) inhalation powder for Raynaud’s phenomenon associated with systemic sclerosis.Key Highlights:Original SEC Filing: Liquidia Corp [ LQDA ] - 8-K - Sep.
03, 2026This is an AI-powered summary.
It may contain inaccuracies.
Conside…